20-F: GSK Reports Strong 2025 Growth, Pipeline Advances, and Leadership Transition

GSK plc delivered robust financial performance in 2025 with significant sales and profit growth, driven by Specialty Medicines and key product approvals, alongside a smooth CEO transition and strategic pipeline investments.

Summary

• Total sales for 2025 reached £32.7 billion, marking a 4% increase at actual exchange rates (AER) and 7% at constant exchange rates (CER).
• Total operating profit surged by 97% AER and over 100% CER to £7,932 million, while Core operating profit grew 7% AER and 11% CER to £9,783 million.
• Total earnings per share increased over 100% AER and CER to 141.1p, and Core earnings per share rose 8% AER and 12% CER to 172.0p.
• Cash generation was strong at £8.9 billion, supporting future investments and shareholder returns, including a 2025 dividend of 66p per share, up from 61p in 2024.
• Specialty Medicines sales grew by 14% AER and 17% CER to £13.5 billion, driven by strong performances in HIV, Respiratory, Immunology & Inflammation, and Oncology.
• Vaccines sales were stable at AER and up 2% CER, reaching £9.2 billion, with strong ex-US demand for Shingrix, Arexvy, and meningitis vaccines.
• General Medicines sales decreased by 4% AER and 1% CER to £10.0 billion, primarily due to generic competition.
• Five major product approvals were achieved in 2025: Exdensur for severe asthma, Blenrep for multiple myeloma, Nucala for COPD, Blujepa for uUTI and uncomplicated gonorrhoea, and Penmenvy for invasive meningococcal disease.
• R&D expense increased by 18% AER and 19% CER to £7.5 billion, reflecting accelerated pipeline progression and strategic acquisitions.
• Net debt increased by £1.4 billion to £14.5 billion at December 31, 2025, primarily due to acquisition costs and shareholder returns.
• A £2 billion share buyback program was announced on February 5, 2025, with £1,377 million repurchased by December 31, 2025.
• Emma Walmsley stepped down as CEO on December 31, 2025, and Luke Miels was appointed CEO effective January 1, 2026.
• The Board approved changes to Non-Executive Director fees and doubled the Share Ownership Requirement (SOR) from 1x to 2x their base fee.
• Several significant legal proceedings saw developments, including global settlements for Coreg and RSV litigation, and the dismissal of a Zantac securities class action lawsuit.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing positively due to strong financial performance, significant R&D progress with multiple key product approvals, and strategic acquisitions that bolster the pipeline. While legal challenges persist, several major disputes have concluded favorably, and the company's commitment to shareholder returns and responsible business practices is evident.

Positives

• Total sales increased by 7% CER to £32.7 billion in 2025, demonstrating strong top-line growth.
• Total operating profit grew by over 100% CER to £7,932 million, indicating significant profitability improvement.
• Core operating profit increased by 11% CER to £9,783 million, reflecting strong underlying business performance.
• Total and Core earnings per share both increased by over 100% CER and 12% CER respectively, showing enhanced shareholder value.
• Cash generation was robust at £8.9 billion, providing ample liquidity for strategic initiatives and shareholder returns.
• The company declared an increased dividend of 66p per share for 2025, up from 61p in 2024, signaling confidence in future performance.
• Five major product approvals were secured in 2025, including Exdensur, Blenrep, Nucala (for COPD), Blujepa, and Penmenvy, significantly strengthening the product portfolio.
• Specialty Medicines achieved double-digit sales growth (17% CER) across HIV, Respiratory, Immunology & Inflammation, and Oncology.
• The R&D pipeline was significantly strengthened through internal progress and targeted business development, including acquisitions of IDRx, BP Asset IX, and RAPT Therapeutics.
• Positive pivotal Phase III data for bepirovirsen in chronic hepatitis B demonstrated a statistically significant and clinically meaningful functional cure rate.
• The company successfully launched Blujepa, the first in a new class of oral antibiotics for uUTIs in nearly 30 years, and for uncomplicated gonorrhoea.
• The global settlement of all RSV litigation with Pfizer, Inc. on April 1, 2025, resolves a significant legal dispute and includes a royalty stream for GSK.
• A confidential settlement was reached with Teva on February 9, 2026, concluding the Coreg patent infringement suit.
• The Zantac qui tam complaint was resolved for $70 million on October 9, 2024, and the putative securities class action lawsuit was dismissed on March 4, 2026.
• The Korea Supreme Court affirmed a not-guilty verdict for GSK Korea in December 2025, concluding the Fair Trade Laws proceedings.
• The Board's commitment to a progressive dividend policy and the initiation of a £2 billion share buyback program underscore shareholder-friendly capital allocation.
• The company entered into an agreement with the US Government in December 2025 to lower prescription medicine costs, potentially strengthening relationships with the US Administration and excluding GSK from s232 tariffs for 3 years.

Negatives

• General Medicines sales declined by 1% CER to £10.0 billion, primarily due to continued generic competition across the portfolio.
• Zejula sales decreased by 4% CER, driven by ongoing volume reductions, impacts of an FDA labeling update restricting use, and IRA Medicare Part D redesign in the US.
• Influenza vaccines sales declined by 24% CER, mainly in the US, due to competitive pressure.
• Established vaccines sales decreased by 5% CER, impacted by divested brands, competitive pressure for Synflorix and Cervarix, and lower US demand and unfavorable pricing for hepatitis vaccines.
• US sales for Shingrix and Arexvy declined due to challenges in reaching harder-to-activate unvaccinated consumers and lower market share for Arexvy.
• The pipeline delivery risk is amplified by complex regulations, shifting pricing and access pressures, and increased scrutiny from payers.
• The development and regulatory approval of new products may be delayed due to limits on relevant authorities' budgets.
• The CD226 axis development program (belrestotug, nelistotug, remsistotug) was discontinued following interim analyses that did not meet efficacy criteria, resulting in a £471 million impairment charge.
• The cobolimab development program was also discontinued based on Phase III COSTAR Lung trial results.
• The Avandia product liability cases continue, with class certification granted and an appeal accepted by the Third Circuit, indicating ongoing legal exposure.
• Approximately 830 ongoing product liability actions related to Legacy Talc Products in the US remain, with no cases having proceeded to trial yet.
• The Zantac litigation, while largely settled in state courts, still has federal MDL appeals pending, with a decision expected in H1 2026, and ongoing class actions in Canada and Israel.
• The Flovent lawsuit by the Arizona Attorney General is ongoing and has been remanded to state court, indicating continued legal defense costs.
• The Lamictal anti-trust litigation continues with discovery ongoing for follow-on complaints after class certification was denied for direct purchasers.
• The Tesaro, Inc. v. AnaptysBio litigation is ongoing, with a trial set for July 2026, representing continued commercial dispute costs and uncertainty.

Risks

• Patient safety: Risk of failing to appropriately collect, assess, follow up, or report human safety information, or failing to act on relevant findings in a timely manner, potentially leading to patient harm, regulatory scrutiny, civil/criminal sanctions, and product marketing authorization revocation.
• Product quality: Risk of failing to ensure appropriate controls and governance of quality for development and commercial products, compliance with industry practices and regulations in manufacturing and distribution, and meeting product license terms, potentially leading to product launch delays, drug shortages, recalls, and regulatory/legal/financial consequences.
• Pipeline delivery: Risk of delays or failures in delivering new medicines, vaccines, or other products due to complex regulations, shifting pricing/access pressures, increased payer scrutiny, rapid changes in healthcare needs, competitive dynamics, and scientific advances.
• Financial controls and reporting: Risk of non-compliance with tax laws, inaccurate financial reporting, or significant losses from treasury activities, potentially leading to regulatory action, litigation, reputational harm, and operational disruption.
• Legal matters: Risk of non-compliance with legal requirements for pipeline development, product commercialization, and business operations, specifically competition law, anti-bribery and corruption, outgoing fraud, and sanctions, potentially leading to governmental investigation, regulatory action, and civil/criminal liability.
• Commercial practices: Risk of engaging in commercial activities that fail to comply with laws, regulations, industry codes, and internal controls due to increased pricing, access, and competitive pressures, potentially leading to investigations, legal actions, and criminal/financial penalties.
• Data ethics and privacy: Risk of failing to ethically collect, use, secure, share, and destroy personal information in accordance with laws, regulations, and internal controls, potentially resulting in legal proceedings, regulatory fines, operational restrictions, and reputational damage.
• Research practices: Risk of failing to adequately conduct ethical and credible pre-clinical and clinical research, or collaborate in research activities compliant with laws, regulations, and internal controls, potentially leading to harm to human subjects, reputational damage, and failure to secure regulatory approvals.
• Environment, health, and safety (EHS): Risk of failing to ensure appropriate controls and governance of assets, facilities, infrastructure, and business activities, including hazardous operations or release of harmful substances, potentially leading to harm to people/environment, fines, and regulatory action.
• Supply continuity: Risk of failing to deliver a continuous supply of compliant finished product or respond effectively to a crisis, potentially leading to product shortages, recalls, regulatory intervention, and lost sales revenue.
• Skills and capability planning: Risk of failing to ensure adequate skills and capability planning to deliver strategic priorities, potentially impacting operations and ability to achieve strategic goals.
• Geopolitical and regulatory environment: Risk of failing to adapt to rising geopolitical and social tensions and changes in the regulatory/legislative environment, potentially leading to restrictive measures, increased costs, and limitations on market access.
• Climate change: Risk of failure in managing physical climate and environmental risks, regulatory requirements for environmental compliance/disclosure/taxes, and delivery of environmental objectives, potentially leading to reduced supply chain resilience, product life cycle management issues, and increased costs.

Future Outlook

The company expects continued momentum and profitable growth in 2026, driven by maximizing launch products like Exdensur and Blenrep, accelerating key late-stage assets, and executing targeted business development. The long-term growth strategy aims to deliver patient benefit at scale and drive competitive growth beyond 2031, with a focus on evolving the company to be more product-centric and leveraging advanced technologies like AI.

Management Comments

• Luke Miels, CEO: "It is a privilege to lead GSK into its next phase of growth as CEO and I am encouraged by the collective determination to realise new levels of performance for patients and shareholders."
• Luke Miels, CEO: "For our growth strategy, I see two clear priorities to create value for shareholders. The first is topline. This means delivering our sales ambition for 2031 and addressing the loss of dolutegravir exclusivity. Second is pipeline. Accelerating R&D is our biggest opportunity to create value as a company."
• Luke Miels, CEO: "We need to go faster with what we have and add to it through smart business development. We also need our labs to produce more competitive products."
• Luke Miels, CEO: "To achieve this, we need to evolve the company. Building on our strong patient-led purpose and culture, we must be more product-centric. Everyone in the company should be clear on how they are helping to bring better products to patients."
• Sir Jonathan Symonds, Chair: "GSK's performance in 2025 exemplified the strengthening of all the fundamentals of the strategy: total sales, total and core operating profit, and total and core earnings per share all grew, driven in particular by very strong performance of Speciality Medicines."
• Sir Jonathan Symonds, Chair: "The Board is very aware that GSK's share price has underperformed for many years and this marks only the start of a long-awaited recovery. Under Luke's leadership we are determined to build on the progress seen during 2025 and continue to deliver significantly improved shareholder returns over the short and longer term."

Industry Context

StockSavvy.ai notes that GSK's strong performance in Specialty Medicines and Vaccines aligns with broader industry trends of increasing demand for innovative therapies in chronic and infectious diseases, particularly in oncology and immunology. The focus on long-acting injectables in HIV and new oral antibiotics for resistant infections positions GSK well against evolving public health challenges like antimicrobial resistance (AMR). The company's significant investment in AI and advanced technologies for R&D and manufacturing reflects a critical industry-wide shift towards digital transformation to enhance productivity and accelerate drug development, a trend also seen in competitors like AstraZeneca and Pfizer. The ongoing pricing pressures and regulatory scrutiny, especially in the US and EU, are consistent across the biopharma sector, necessitating strategic engagement with governments to balance affordability and innovation. GSK's proactive approach to environmental sustainability, including the development of low-carbon inhalers, also addresses growing stakeholder and regulatory demands for responsible business practices within the industry.

Comparison to Industry Standards

• GSK's 2025 total sales growth of 7% CER and core operating profit growth of 11% CER are competitive within the global biopharma sector, especially given the strong performance of Specialty Medicines.
• The company's R&D expense of £7.5 billion in 2025, representing 23% of sales, indicates a significant commitment to innovation, comparable to leading pharmaceutical companies like Pfizer and AstraZeneca.
• The five major product approvals in 2025, including Exdensur, Blenrep, Nucala (for COPD), Blujepa, and Penmenvy, demonstrate strong pipeline execution and competitive product launches against peers.
• GSK's leadership in HIV innovation, particularly with long-acting injectables like Cabenuva and Apretude, sets a high standard in a critical therapeutic area, differentiating it from companies with less focus on this segment.
• The development of Blujepa as the first new class of oral antibiotics for uUTIs in nearly 30 years addresses a significant unmet need in antimicrobial resistance, a global health threat that many pharmaceutical companies are struggling to tackle effectively.
• The company's commitment to net zero and nature positive goals, with SBTi-approved targets, positions it among the leaders in environmental sustainability within the pharmaceutical industry, exceeding the efforts of some competitors in integrating ESG into core operations.
• The CEO's starting salary of £1.375 million is approximately 4% lower than the predecessor's 2025 base salary and 5.5% lower than the global biopharma peer group median, placing total pay in the lower quartile, indicating a more conservative approach to executive compensation compared to some industry benchmarks.

Management Changes

Corporate Governance

Legal Proceedings

• Breo Ellipta: GSK filed a patent and trademark infringement suit against Transpire Bio Inc. on September 25, 2025, with a trial date set for November 2, 2026.
• Coreg: GSK and Teva reached a confidential settlement on February 9, 2026, dismissing the patent infringement action with prejudice, concluding the matter.
• mRNA (COMIRNATY, SPIKEVAX, mRESVIA): GSK filed multiple patent infringement suits against Pfizer/BioNTech and Moderna in the US, UPC, and Spain between 2024 and 2026, with trials scheduled for 2026-2027. Acuitas Therapeutics Inc. also filed a declaratory judgment complaint against GSK on January 2, 2025.
• RSV (Abrysvo): GSK and Pfizer reached a global settlement on April 1, 2025, granting Pfizer a worldwide license to certain GSK patents in exchange for a royalty stream on Abrysvo sales, concluding all related litigation.
• Trelegy Ellipta: GSK received a paragraph IV letter from Transpire on January 22, 2026, and is assessing its options.
• Zejula: GSK filed a patent infringement suit against Sun Pharmaceutical Industries Limited on September 19, 2025, with a trial date set for July 24, 2028.
• Avandia: Two US class actions are pending, with class certification granted on May 22, 2025, and an appeal accepted by the Third Circuit on July 7, 2025. Oral argument was held on February 26, 2026, and proceedings are stayed pending the appeal outcome.
• Legacy Talc Products in the US: Approximately 830 ongoing product liability actions are pending, alleging asbestos-contaminated talc exposure and mesothelioma, with no cases having proceeded to trial to date.
• Zantac: GSK resolved 93% (approx. 80,000 claimants) of state court product liability cases on October 9, 2024, and settled a qui tam complaint for $70 million. The Delaware Supreme Court reversed a lower court's decision on July 10, 2025, and the Delaware Superior Court denied supplemental expert disclosures on December 1, 2025. Federal MDL appeals are ongoing, with a decision expected in H1 2026. A putative securities class action lawsuit was dismissed on March 4, 2026.
• Zofran: The MDL Court granted summary judgment for GSK on June 1, 2021, which was affirmed by the First Circuit on January 9, 2023. The one remaining state court case was voluntarily dismissed in July 2025, and Canadian class actions are expected to be discontinued, concluding the matter.
• Flovent Arizona Attorney General: A lawsuit alleging deceptive and unfair practices was filed on February 6, 2025, remanded to state court on August 26, 2025, with oral argument on a motion to dismiss held on January 23, 2026.
• GSK Korea Fair Trade Laws: The Korea Supreme Court affirmed a not-guilty verdict in December 2025, concluding the proceedings related to government tenders of HPV and PCV vaccines.
• US electronic health records subpoena: GSK received a subpoena on March 19, 2023, and cooperated with the inquiry.
• Senate HELP Enquiry: GSK received a letter on January 8, 2024, initiating an investigation into inhaler pricing and cooperated with the inquiry.
• Lamictal: Class certification for direct purchasers was denied on February 1, 2023, with discovery ongoing for follow-on complaints.
• Tesaro, Inc. v. AnaptysBio: Tesaro initiated litigation on November 20, 2025, and GSK's motion to dismiss AnaptysBio's amended complaint was granted on March 4, 2026. A trial is set for July 14-17, 2026.
• Zejula royalty dispute: The Court of Appeal ruled in GSK's favor on February 9, 2024, and the UK Supreme Court rejected AstraZeneca's appeal on May 28, 2024. The appropriate quantum of royalties may be subject to further proceedings.

Related Party Transactions

• No outstanding loans due to GSK from Index Ventures or Medicxi Ventures I LP at December 31, 2025.
• Cash distributions were received from Medicxi Ventures I LP (£62 million), Index Ventures l LP (£2.3 million), and Kurma Biofund II FCPR (£2.3 million).
• No other significant related party transactions were disclosed that might reasonably be expected to influence decisions made by the users of these financial statements.

Stakeholder Impact

• Shareholders: Expected to benefit from increased dividends (66p per share for 2025, 70p expected for 2026) and a £2 billion share buyback program, reflecting strong financial performance and commitment to shareholder returns. The share price increased by 36% in 2025.
• Patients: Directly impacted by the five major product approvals in 2025 (Exdensur, Blenrep, Nucala for COPD, Blujepa, Penmenvy), offering new or improved treatment and prevention options for severe asthma, multiple myeloma, COPD, uUTIs, gonorrhoea, and meningococcal disease. The focus on long-acting HIV treatments and new antibiotics addresses significant unmet medical needs.
• Employees: The CEO transition and Executive Committee restructuring aim to enhance strategic execution and foster a product-centric culture, potentially leading to new opportunities and increased accountability. The company's commitment to inclusion and talent development, including AI capabilities, supports employee growth. However, restructuring programs may involve staff reductions in some areas.
• Healthcare Providers: New product approvals and expanded indications provide more treatment options. The development of low-carbon inhalers and efforts to combat antimicrobial resistance contribute to sustainable healthcare practices.
• Governments and Regulators: Engaged in discussions regarding pricing and access to medicines, as evidenced by the agreement with the US Administration to lower prescription medicine costs. Compliance with evolving regulations, including those related to data ethics, cyber security, and environmental standards, remains a key focus. Ongoing legal proceedings, such as Zantac and patent disputes, highlight regulatory scrutiny.
• Suppliers and Partners: Business development activities, including acquisitions and collaborations (e.g., Hengrui Pharma, Empirico, LTZ Therapeutics), create opportunities for partners. The focus on resilient supply chains and sustainable sourcing impacts suppliers. The sale of Human Genome Sciences equity investment to Samsung Biologics represents a change in partnership structure.

Next Steps

• Execute excellent launches of newly approved products, including Exdensur and Blenrep.
• Accelerate key assets in the late-stage portfolio, such as oncology ADCs and long-acting TSLP for COPD.
• Continue targeted business development to further strengthen the pipeline.
• Initiate Phase III registrational study for CAB-ULA (ultra-long-acting cabotegravir) four-monthly treatment option in 2026.
• Progress the AI Governance Council's key focus areas, including strengthening controls for autonomous AI systems and completing an external benchmarking exercise.
• Implement updated Key Risk Indicators (KRIs) for cyber security in phases, with controlled introduction completed by end of 2026.
• Continue to refine the Responsible Business strategy during 2026.
• Conclude the external audit contract tender process in summer 2026, with the new auditor appointed for January 1, 2028.
• Hold the Annual General Meeting (AGM) on May 6, 2026.
• Disclose provisional accounting for the RAPT Therapeutics acquisition in the Q1 2026 Results Announcement.
• Complete the acquisition of 35Pharma Inc., subject to regulatory clearances.
• Complete the sale of Human Genome Sciences equity investment to Samsung Biologics towards the end of Q1 2026.
• Conduct an external evaluation review of the Board and its committees in the first half of 2026.
• Hold oral argument for the Avandia class certification appeal on February 26, 2026.
• Trial for Breo patent infringement suit against Transpire Bio Inc. scheduled for November 2, 2026.
• Trial for COMIRNATY patent infringement suit against Pfizer/BioNTech scheduled for June 7, 2027.
• Trial for SPIKEVAX patent infringement suit against Moderna scheduled for July 19, 2027.
• Trial for mRESVIA patent infringement suit against Moderna scheduled for August 23, 2027.
• Hearing window for Moderna UPC patent infringement suit scheduled for September 1-3, 2026.
• Hearing window for second Moderna UPC patent infringement suit scheduled for September 30 October 2, 2026.
• Hearing window for Pfizer/BioNTech UPC patent infringement suit scheduled for September 1-3, 2026.
• Hearing window for second Pfizer/BioNTech UPC patent infringement suit scheduled for September 30 October 2, 2026.
• Trial listed for Pfizer/BioNTech UK Patents Court suit for February 22, 2027.
• Oral argument on Flovent motion to dismiss scheduled for January 23, 2026.
• Trial for Tesaro, Inc. v. AnaptysBio litigation set for July 14-17, 2026.
• Trial date set for Zejula patent infringement suit against Sun Pharmaceutical Industries Limited for July 24, 2028.

Key Dates

Recommendation

The filing indicates a strong 'buy' recommendation for a seasoned investor or institution. GSK has demonstrated exceptional financial performance in 2025, with significant growth in total and core operating profit and EPS, driven by its high-value Specialty Medicines portfolio. The company's R&D pipeline is robust, evidenced by five major product approvals and strategic acquisitions that promise future growth. The commitment to a progressive dividend policy and a substantial share buyback program signals strong shareholder returns. While ongoing legal challenges exist, several significant disputes have been favorably resolved or dismissed, reducing long-term uncertainty. The new CEO's focus on strategic execution, pipeline acceleration, and technology adoption positions GSK for sustained competitive advantage and value creation.

Keywords

Pharmaceuticals, Vaccines, Biopharma, Specialty Medicines, HIV, Oncology, Respiratory, Immunology, Infectious Diseases, R&D, Product Approvals, SEC Filing, Financial Performance, Debt Securities, Corporate Governance, Legal Proceedings, Share Buyback, Dividend, Climate Change, AI, Digital Transformation